Thrombosis and Haemostasis: Volume 100 and going strong ….

References
1 Preissner KT. 50 years Thrombosis and Haemostasis (1957–2007): keeping thoughts and blood in flow. Thromb Haemost 2007; 98: 1-2.
2 Hirsch E. Signal transduction in inflammation. Perspective clues from the leukocyte-endothelium interface. Thromb Haemost 2006; 95: 3-4.
3 Weitz JI. Emerging themes in the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 239-241.
4 Schrör K, Weber AA. COX-2 inhibitors and the thrombotic risk. Thromb Haemost 2006; 96: 391-392.
5 Mannhalter C, Quehenberger P. Laboratory methods in the haemostatic laboratory. Thromb Haemost 2006; 96: 545-546.
6 Binder BR. Signaling in endothelial cells. Thromb Haemost 2007; 97: 334-335.
7 Görlach A. The response to cardiovascular injury: A field of emerging complexity. Thromb Haemost 2007; 98: 259-261.
8 Görlach A. Vascular remodelling processes: cells, signals and their integration. Thromb Haemost 2007; 98: 919-21.
9 Herwald H. Haemostasis, vascular biology and infectious agents. Thromb Haemost 2007; 98: 483-484.
10 Garcia de Frutos P. Mechanisms of thrombophilia. Thromb Haemost 2007; 98: 485-487.
11 Lip GYH. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost 2008; 100: 11-13.
12 Mant JW. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation. Thromb Haemost 2008; 100: 14-15.
13 Hylek EM. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb Haemost 2008; 100: 16-17.